Cannabis Industry News

In the past 48 hours, the cannabis industry presents mixed signals, with regulatory delays in the U.S. overshadowing modest market expansions and stock volatility.[1] Virginia Governor Abigail Spanberger proposed amendments to delay recreational marijuana sales from January 1, 2027, to July 1, 2027, aiming to build a safer legal market and curb illicit trade; she also seeks to raise the excise tax from 6 percent to 8 percent after 2029 and cap initial retail licenses at 200 instead of 350.[3][8][10] Lawmakers will review these on April 22.[8]

Stock-wise, Tilray Brands (TLRY), Canopy Growth (CGC), and Cronos Group (CRON) led trading volume on April 14, signaling investor focus amid broader uncertainty.[2] Globally, Canada exported about 240 tonnes in 2025, doubling 2024's 107 tonnes, while Thailand emerges as a low-cost medical supply contender.[4] In Germany, CATHAROS launched a medical cannabis marketplace partnering with iA.de.[6]

No major deals, partnerships, or product launches surfaced in the last 48 hours, but New York's five-year-old market generates billions despite rollout complaints from Buffalo owners.[5] California's consumption lounges shifted from West Hollywood to Hawthorne amid regulations.[6]

Compared to prior weeks, Virginia's delay marks a setback from assembly-passed timelines, contrasting optimistic 2024 reform momentum now tempered by 2026 tightening risks like Germany's telemedicine curbs.[4] Consumer behavior shows 4/20 losing peak status in DMV markets, with pre-holiday weeks outpacing the day itself.[12] Leaders like existing Virginia operators eye conversion fees of $10 million to enter adult-use.[8] Overall, caution prevails as prices face compression from oversupply.[4]

(Word count: 248)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the cannabis industry shows mixed signals with regulatory delays offsetting market expansions and stock volatility. Rhode Islands preliminary injunction last week halted new cannabis licensing, extending a four-year pattern that benefits incumbent dispensaries while financially straining social equity applicants and cultivators, who face ongoing monthly costs amid an oligopolistic market[1]. This self-inflicted fallout, as noted by the court, forgoes millions in state tax revenue and destabilizes the sector.

On expansion fronts, Alabama prepared to open its first medical cannabis dispensary last week after years of hurdles, marking a key milestone[3]. In California, Glass House Brands announced a major retail joint venture with Vireo Growth, combining 11 Glass House stores with a preferential supply deal and 12 Vireo dispensaries plus home delivery, boosting operational scale[8].

Stock-wise, MarketBeats April 13 screener flagged seven high-volume cannabis names: Tilray Brands, Canopy Growth, WM Technology, SNDL, Aurora Cannabis, Cronos Group, and Silver Spike Investment, spanning cultivation to fintech amid high volatility tied to policy shifts[2]. No specific price changes or consumer behavior stats emerged from the past week, though NORMLs ongoing 2026 Cannabis Freedom Survey probes possession freedoms and legal fears ahead of 420, signaling persistent consumer concerns[9].

Compared to prior reports, this builds on chronic licensing delays without major disruptions, while medical market projections to 2033 highlight long-term growth from legalization and therapeutics[6]. Leaders like Glass House respond via strategic ventures to counter oligopoly pressures. Overall, innovation leans commercial post-legalization, not always patient-focused[7], with no verified supply chain shifts or new launches in the latest window.

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the cannabis industry shows mixed signals amid regulatory shifts and market pressures. The U.S. Justice Department proposed reclassifying marijuana from Schedule I to Schedule III, recognizing its medical uses and lower abuse potential compared to drugs like heroin, a move echoing President Trumps prior order and potentially easing banking and research barriers.[1] This comes as North Carolinas state council urged adult-use legalization on April 7, signaling growing momentum.[10]

Market movements reflect caution: Aurora Cannabis short interest rose 2.2 percent to 7.37 million shares as of January 15, 2026, with 11.6 percent of float shorted, amid a stock price near 5.25 dollars.[8] Michigan saw continued sales declines due to saturation and pricing pressures, mirroring mature markets and risking patient supply disruptions.[6] WM Technology announced Nasdaq delisting over compliance and low volume issues.[2]

Deals and expansions heat up in Texas, where Green Thumb Industries and Cresco Labs plan medical market entry, joining Trulieve and Verano with preliminary approvals.[2] New Yorkers discussed industry impacts on April 13, highlighting local economic effects.[3]

Product launches include San Franciscos 420 Space Walk fest debuting Sense Cannabis Yuzu Sour strain and Sunset Connects new flavors from April 14-20.[7] Internationally, Moldovan scientists pioneered hemp-fortified bread post-2023 legalization, boosting byproduct innovation.[5]

Challenges loom for hemp farmers facing planting bans, creating supply chain volatility for CBD products and forcing patient adjustments.[4] Leaders like Dr. Caplan advise backup therapies amid instability.[4][6]

Compared to prior weeks, sales dips persist from oversupply, but federal rescheduling and Texas moves contrast earlier stagnation, hinting at recovery if policies advance. Consumer behavior shifts toward medical stability, with travel to cannabis-friendly spots rising in 2026 forecasts.[9] Massachusetts cannabis salaries average 91,800 dollars yearly.[11]

(Word count: 298)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the cannabis industry shows resilience amid regulatory flux and market challenges, with Tilray Brands posting strong Q3 results ending February 28, including 19 percent cannabis revenue growth to 64.8 million dollars, offsetting beverage declines as consumers shift from alcohol[2][4][11]. Canadian government data confirms rising marijuana sales against falling alcohol purchases, signaling sustained behavioral changes[4][11].

Regulatory shifts dominate: Massachusetts lawmakers passed a bill overhauling the Cannabis Control Commission, doubling adult possession to two ounces, and raising license caps to six per owner, awaiting Governor Healey's signature[3][4]. Kentucky advances medical sales, with vape cartridges from Toro Infused hitting shelves as early as Friday and concentrates by mid-summer[1]. Texas faces backlash, as a lawsuit challenges March 31 bans on smokable hemp like ATX Organics products[5].

Deals and launches include Vireo Growth completing its Hawthorne acquisition from ScottsMiracleGro, adding dispensaries in Colorado and New Mexico[6], and New Jersey debuting ButACake's canned Cherry Hibiscus Elixir[9]. Partnerships feature Ascend Wellness with NuProject for small business support, and Snoop Dogg's Death Row Records with Sensi Seeds for new strains[4].

Price deflation and competition pressure growth, yet Curaleaf rallied 6.7 percent on recovery bets, with Q1 earnings eyed May 5[8][13]. Tilray eyes U.S. CBD via Medicare's pilot, negotiating FDA standards[2]. Ethos Cannabis skips 4/20 sales frenzy for a month-long education campaign, prioritizing intentional use[10].

Compared to prior weeks, organic growth like Tilray's bucks acquisition-driven trends, while hemp restrictions intensify versus earlier expansions. Leaders respond by innovating products and lobbying, navigating disruptions without major halts[1][2]. Word count: 298

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the U.S. cannabis industry faces intensifying regulatory pressures in Texas alongside market optimism elsewhere. Texas hemp businesses, including the Texas Hemp Business Council and dispensaries, filed a lawsuit on Tuesday against the Department of State Health Services to block rules effective March 31 that ban smokeable hemp products like THCA flower and pre-rolls, while hiking manufacturer licensing fees from 258 dollars to 10,000 dollars annually.[1][2][3][5][7][9][11] Owners report 50 to 60 percent sales drops, fearing closures, as labs now test total THC exceeding 0.3 percent, even if inactive until heated.[1][3] A temporary restraining order hearing is set for Friday.[3]

Nationally, stocks show momentum: Trees Corp surged 14.3 percent to 0.03 dollars on heavy volume.[2] Vireo Growth acquired Scotts Miracle-Gros hydroponics unit for 128 million dollars in stock, bolstering its balance sheet.[2] On April 7, Sensi Seeds launched U.S. exclusive strains partnering with Death Row Records.[4]

In Massachusetts, lawmakers unanimously passed a bill Wednesday to double adult possession to two ounces, restructure the Cannabis Control Commission, allow up to six licenses per entity, and prioritize social equity, with Senate approval expected soon.[6]

Market data highlights shifts: Cannabis drinks are projected to hit 1.37 billion dollars in 2026, up from 1 billion in 2025, with a 37.3 percent CAGR to 23.8 billion by 2036, driven by nanoemulsion tech and wellness trends; alcoholic-infused types hold 57.8 percent share.[10]

Compared to last week, Texas disruptions escalated from rule finalization on March 20, prompting immediate suits versus prior delta-8 battles now before the Supreme Court.[1] Leaders respond via litigation to preserve access, while acquisitions and product launches signal resilience amid consumer pivot to beverages and regulated formats. No major supply chain issues or price stats emerged this week.

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the cannabis industry grapples with mounting federal hemp THC restrictions and state-level reforms amid stock plunges and business pivots. A looming federal law set for November bans hemp products exceeding 0.4 milligrams of THC per serving, endangering Minnesotas 180 million dollar hemp THC drink and edibles market from last year, prompting companies like Trail Magicwhich ships to 25 statesto shift to nonTHC alternatives such as 2.9 percent alcohol drinks or adaptogen beverages, with owners fearing brewery closures absent congressional action.[1]

Massachusetts finalized reform legislation on April 6, shrinking the Cannabis Control Commission to three governorappointed members, doubling retailer licenses to six stores per holder, ending medical marijuana vertical integration, and raising possession limits to two ounces.[2][6][8] In North Carolina, Governor Josh Stein endorsed a council report on April 6 highlighting a multibilliondollar unregulated marketestimated at 3 billion dollars in annual illegal salescalling for adultuse legalization and THC rules.[3][4]

Market volatility intensified, with TPCO Holding shares dropping 13 percent to 0.16 dollars on April 6 on 86353 shares volume, capping it at 45.7 million dollars, reflecting pessimism for small firms; IM Cannabis raised 250000 dollars via convertible notes repayable in shares, signaling funding woes.[1][6][10] No major deals, launches, or disruptions surfaced, though seasonal 4/20 ramps loom in prerolls, vapes, and edibles, with flower at 50 percent of sales.[1][8]

Compared to prior weeks, focus sharpened on federal hemp threats over state gains, sans rescheduling progress or consumer shifts; leaders like Trail Magic adapt proactively amid stagnant data.[1][4] Broader stats show 2025 U.S. economic impact at 149 billion dollars, medical legal in 42 states, and top markets like California at 4.27 billion dollars in 2024 sales.[5] Volatility endures, but multi state operators like Trulieve and Cresco eye long term growth.[2]

(Word count: 298)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the cannabis industry faces intensifying regulatory pressures and market volatility, with federal hemp restrictions looming large while states push reforms.

A federal law set in for November will ban hemp products exceeding 0.4 milligrams of THC per serving, threatening Minnesotas 180 million dollar hemp THC drink and edibles market from last year. Businesses like Trail Magic, which ships to 25 states, report retailers pulling back orders ahead of the change, forcing pivots to non-THC alternatives like 2.9 percent alcohol drinks or adaptogen beverages. Owners warn of brewery closures without congressional reversal.[1][5][11]

In Massachusetts, reform legislation finalized April 6 downsizes the Cannabis Control Commission to three governor-appointed members, doubles retailer licenses to six stores per holder, ends medical marijuana vertical integration, and raises possession limits to two ounces.[2]

North Carolina Governor Josh Stein endorsed his councils report on April 6, calling the states multibillion-dollar unregulated market crying for order through adult-use legalization and robust THC regulations.[3][4]

Market wise, TPCO Holding shares plunged 13 percent to 0.16 dollars on April 6 amid high volume of 86,353 shares, shrinking its cap to 45.7 million dollars and signaling sector pessimism for small ancillary firms.[6] IM Cannabis raised 250,000 dollars via convertible note and warrants the same day, repayable only in shares, underscoring funding strains.[10]

No major new deals, product launches, or supply disruptions emerged, but seasonal trends project spring sales ramps in pre-rolls, vapes, and edibles toward 4/20, with flower steady at 50 percent of sales.[8]

Compared to prior weeks, this periods focus sharpens on federal hemp fallout versus states piecemeal advances, with leaders like Trail Magic proactively adapting amid stagnant consumer data. Volatility persists without rescheduling breakthroughs.[4]

Word count: 298

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the U.S. cannabis industry shows robust growth amid supply concerns and regulatory momentum. New Yorks market has stabilized with over 600 dispensaries open and legal sales exceeding 3 billion dollars, though officials flag potential shortages as wholesaler Nabis handles 15 percent of supply from Rochester[1]. Florida medical marijuana sales hit 5.51 billion milligrams of THC and 1.87 million ounces of smokable flower as of April 2, while Rhode Island tallied 10.03 million dollars in March sales, up nearly 5 percent from 2025s first quarter[4].

Stock markets spotlight Tilray Brands, Canopy Growth, and Aurora Cannabis for high trading volume on April 5, signaling investor focus on global players amid tax reform talks[2]. Regulatory shifts accelerate: New York approved 27 new adult-use licenses, totaling over 2,200, and advanced event sales rules[4]. Louisiana senators greenlit hospital use of medical cannabis for terminal patients[8]. North Carolinas advisory council decried the unregulated 1 billion-dollar hemp market as a wild west, urging an adult-use system to curb 600 percent ER visit surges and generate revenue[7]. Massachusetts faces a lawsuit to block a ballot initiative threatening 800 businesses and thousands of jobs[5].

Leaders respond decisively: Producers in New York argue surging demand will bolster prices and stability against shortages[1]. Fullerton, California, proposes immediate fines for unlicensed operations under new state law[6]. Compared to prior weeks, sales growth outpaces last year in key states, but hemp crackdowns and lawsuits introduce volatility versus steadier medical expansions. No major deals, launches, or consumer shifts reported, though federal rescheduling buzz persists via Trump advisor comments[4]. Overall, expansion trumps disruptions.

(Word count: 298)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

CANNABIS INDUSTRY STATE ANALYSIS: PAST 48 HOURS

The U.S. cannabis market continues its expansion with notable developments emerging from multiple states over the past two days.

Minnesota's recreational cannabis market shows solid momentum. Since September 2025, when the Office of Cannabis Management issued first retail licenses, sales have exceeded 50 million dollars. For all of 2025, combined adult-use marijuana and hemp-derived THC product sales reached 210 million dollars, generating 27 million dollars in new state tax revenue. Executive Director Eric Taubel expects monthly sales to double in coming months as roughly 180 licenses remain in operation, predominantly microbusinesses designed to support craft-oriented competition.

Supply chain challenges persist across the sector. Minnesota faced testing facility bottlenecks, prompting Governor Tim Walz to recently sign bipartisan legislation allowing out-of-state testing for hemp-derived products to relieve pressure. Taubel reports that supply issues have eased somewhat as early cultivator licenses' plants have fully matured and begun consistent production. Additional tribal partners through recent compacts are expected to further increase product availability.

On the corporate front, Green Thumb Industries, a leading multistate operator, amended its brand licensing agreements effective April 1, 2026. The company transitioned from revenue-based fees to a fixed 70 million dollar annual payment to RYTHM Inc. subsidiaries for brands including RYTHM, incredibles, Beboe, and others. This shift provides cost predictability as the company navigates retail expansion during market maturation.

Regulatory innovation emerged from Washington D.C., where Mayor Muriel Bowser proposed the Medical Cannabis Beverage Product Amendment Act of 2026. This legislation would allow medical marijuana companies to partner with local breweries and distilleries to produce cannabis-infused, alcohol-free beverages. Breweries and distilleries could apply for manufacturing endorsements at 500 dollars annually, while cannabis companies pay 1,000 dollars to import cannabinoids.

Consumer behavior continues shifting. Retailers report increased focus on wellness-oriented products, including low-dose edibles and CBD-rich formulations. Industry data shows a 65 percent increase in unique cannabis buyers overall.

The market demonstrates maturation characteristics despite ongoing growing pains. Regulatory frameworks are evolving to address production challenges while supporting local business ecosystems, though supply consistency and testing infrastructure remain areas requiring attention as the industry expands nationwide.

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.

In the past 48 hours, the cannabis industry shows mixed signals with key partnerships boosting stability amid regulatory pressures and softening sales. RYTHM Inc secured a landmark revised licensing deal with Green Thumb Industries, effective April 1, 2026, guaranteeing 70 million dollars in annual fixed revenue starting this year, escalating by double the Consumer Price Index annually for brands like RYTHM, incredibles, and Beboe. This shift from revenue shares to predictable cash flow highlights leaders prioritizing investor confidence in a volatile market.[2][13]

Regulatory headwinds dominate: Missouris Senate approved a bill Tuesday banning intoxicating hemp products over 0.4 milligrams THC per container, aligning with federal limits and adding marijuana privacy protections plus union rights for cannabis workers; it awaits House reconciliation.[3] Georgias synthetic hemp ban bill races a Thursday deadline, threatening 20 percent revenue cuts for shops.[5] Federally, the White House Office of Management and Budget met Wednesday with industry reps on CBD enforcement policies, amid delays in Trumps cannabis rescheduling push.[6]

Market data from recent weeks reveals declines: Michigan February sales hit 234.6 million dollars, down 3 percent year-over-year but up 3.4 percent sequentially; national U.S. sales in 15 states fell 3.6 percent in February per BDSA.[7][8] States like New York up 43 percent in stores, Ohio 19 percent, and New Jersey 9 percent show expansion, though overall growth slowed to about 10 percent CAGR since 2020.[1]

No major new launches or disruptions emerged, but WEED Inc eyes AI data centers and crypto settlements to ease cash woes.[4] Compared to prior months, sales dips persist from Januarys 8.4 percent Canada drop and Michigans 15.9 percent sequential fall, signaling saturated markets and consumer caution amid regs.[7] Leaders like RYTHM respond by locking in fixed revenues, contrasting earlier revenue-tied volatility. Outlook tempers on hemp bans but brightens on multistate growth. (298 words)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI.